MaxCyte to Present on Development of Novel Tumor-Targeted Enhanced Potency T Cell Immunotherapy at The 15th Annual Meeting of the International Society of Cellular Therapy (ISCT)

MaxCyte will be presenting results on the development of an engineered tumor-targeted T cell therapy uniquely enabled by the use of MaxCyte GTFlow Transfection System at the 15th Annual Meeting of the International Society of Cellular Therapy (ISCT) in San... [more]

View complete Press Release article